Product Description | Recombinant CHO-K1 cells stably overexpress human adenosine A2A receptor (ADORA2A) on the surface and contain high levels of G protein Gαs to couple with the receptor in downstream signaling pathways. |
Culture Properties | Adherent. |
Stability | Stable through more than 16 passages with no significant changes in assay performance or expression profile. |
Size | Two vials of frozen cells (>1×106 per vial in 1 mL). |
Storage | Store cells in liquid nitrogen immediately upon receipt. Thaw and recover cells within one year from the date received. |
Culture Medium | Ham’s F-12K (Kaighn’s), 10% FBS, 200 μg/ml Zeocin (Cat. No. R250-01, Life Technologies), 100 μg/ml Hygromycin B (Cat. No. 10687010, Life Technologies) |
Complete Growth Medium | Ham’s F-12K (Kaighn’s), 10% FBS |
Freeze Medium-DATA | 45% Ham’s F-12K (Kaighn’s) (Cat. No. 21127, Life Technologies), 45% FBS (Cat. No. 10099-141, Life Technologies), 10% DMSO (Cat. No. D2650, Sigma). |
Figure 1. Dose dependent stimulation of intracellular cAMP accumulation upon treatment with NECA in CHO-K1/ADORA2A/Gα15 cells. d2 acceptor fluorophore -labeled cAMP (Cat. No. 62AM4PEC; Revvity) and intracellular cAMP in CHO-K1/ADORA2A/Gα15 cells competitively bind with Europium Cryptate-labeled anti-cAMP monoclonal antibody. The FRET signal decreases as the intracellular cAMP concentration rises and was measured by plate reader (Pherastar, BMG). The EC50 of NECA on CHO-K1/ADORA2A/Gα15 cells was 2.01 nM. »
Figure 1. Dose dependent stimulation of intracellular cAMP accumulation upon treatment with NECA in CHO-K1/ADORA2A/Gα15 cells. d2 acceptor fluorophore -labeled cAMP (Cat. No. 62AM4PEC; Revvity) and intracellular cAMP in CHO-K1/ADORA2A/Gα15 cells competitively bind with Europium Cryptate-labeled anti-cAMP monoclonal antibody. The FRET signal decreases as the intracellular cAMP concentration rises and was measured by plate reader (Pherastar, BMG). The EC50 of NECA on CHO-K1/ADORA2A/Gα15 cells was 2.01 nM.
»
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.